Profound Medical to Release Fourth Quarter and Full Year 2024 Financial Results on March 6 – Conference Call to Follow
Profound Medical Corp (NASDAQ:PROF; TSX:PRN), a commercial-stage medical device company specializing in incision-free ablation therapies for diseased tissue, has announced it will release its fourth quarter and full year 2024 financial results after market close on Thursday, March 6, 2025.
The company will host a conference call at 4:30 p.m. ET on the same day, where management will review financial results and discuss business developments. The call will be accessible through online registration and will also be broadcast live and archived on the company's website under the Investors section.
Profound Medical Corp (NASDAQ:PROF; TSX:PRN), un'azienda di dispositivi medici in fase commerciale specializzata in terapie di ablazione senza incisioni per tessuti malati, ha annunciato che rilascerà i suoi risultati finanziari del quarto trimestre e dell'intero anno 2024 dopo la chiusura del mercato il giovedì 6 marzo 2025.
L'azienda ospiterà una conferenza telefonica alle 16:30 ET lo stesso giorno, durante la quale la direzione esaminerà i risultati finanziari e discuterà degli sviluppi aziendali. La chiamata sarà accessibile tramite registrazione online e sarà anche trasmessa in diretta e archiviata sul sito web dell'azienda nella sezione Investitori.
Profound Medical Corp (NASDAQ:PROF; TSX:PRN), una empresa de dispositivos médicos en etapa comercial especializada en terapias de ablación sin incisiones para tejidos enfermos, ha anunciado que publicará sus resultados financieros del cuarto trimestre y del año completo 2024 después del cierre del mercado el jueves 6 de marzo de 2025.
La empresa llevará a cabo una conferencia telefónica a las 4:30 p.m. ET el mismo día, donde la gerencia revisará los resultados financieros y discutirá los desarrollos comerciales. La llamada será accesible mediante registro en línea y también se transmitirá en vivo y se archivará en el sitio web de la empresa en la sección de Inversores.
Profound Medical Corp (NASDAQ:PROF; TSX:PRN)은 질병이 있는 조직에 대한 절개 없는 절제 요법을 전문으로 하는 상업 단계의 의료 기기 회사로, 2024년 4분기 및 전체 연도 재무 결과를 2025년 3월 6일 목요일에 시장 종료 후 발표할 것이라고 발표했습니다.
회사는 같은 날 오후 4시 30분 ET에 컨퍼런스 콜을 개최하며, 경영진이 재무 결과를 검토하고 비즈니스 개발에 대해 논의할 것입니다. 이 전화는 온라인 등록을 통해 접근 가능하며, 회사 웹사이트의 투자자 섹션에서 실시간 방송 및 아카이브됩니다.
Profound Medical Corp (NASDAQ:PROF; TSX:PRN), une entreprise de dispositifs médicaux en phase commerciale spécialisée dans les thérapies d'ablation sans incision pour les tissus malades, a annoncé qu'elle publiera ses résultats financiers du quatrième trimestre et de l'année complète 2024 après la fermeture du marché le jeudi 6 mars 2025.
L'entreprise organisera une conférence téléphonique à 16h30 ET le même jour, au cours de laquelle la direction examinera les résultats financiers et discutera des développements commerciaux. L'appel sera accessible par inscription en ligne et sera également diffusé en direct et archivé sur le site web de l'entreprise dans la section Investisseurs.
Profound Medical Corp (NASDAQ:PROF; TSX:PRN), ein kommerzielles Medizintechnikunternehmen, das sich auf schnittfreie Ablationstherapien für erkranktes Gewebe spezialisiert hat, hat angekündigt, dass es seine Finanzergebnisse für das vierte Quartal und das Gesamtjahr 2024 nach Marktschluss am Donnerstag, den 6. März 2025 veröffentlichen wird.
Das Unternehmen wird am selben Tag um 16:30 Uhr ET eine Telefonkonferenz abhalten, in der das Management die Finanzergebnisse überprüfen und Geschäftsentwicklungen besprechen wird. Die Konferenz wird über eine Online-Registrierung zugänglich sein und auch live übertragen sowie im Bereich Investoren auf der Unternehmenswebsite archiviert.
- None.
- None.
TORONTO, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its fourth quarter and full year 2024 financial results after market close on Thursday, March 6, 2025.
Profound management will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in the period.
Fourth Quarter and Full Year 2024 Results Conference Call Details:
Date: Thursday, March 6, 2025
Time: 4:30 p.m. ET
Live Call Registration: https://register.vevent.com/register/BI4fc1c4c3061645ca9f513f8f017abfbb
The call will also be broadcast live and archived on the Company's website at www.profoundmedical.com under “Webcasts” in the Investors section.
About Profound Medical Corp.
Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue.
Profound is commercializing TULSA-PRO®, a technology that combines real-time MRI, robotically-driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA procedure, performed using the TULSA-PRO® system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low-, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (“BPH”); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. TULSA employs real-time MR guidance for precision to preserve patients’ urinary continence and sexual function, while killing the targeted prostate tissue via precise sound absorption technology that gently heats it to 55-57°C. TULSA is an incision- and radiation-free “one-and-done” procedure performed in a single session that takes a few hours. Virtually all prostate shapes and sizes can be safely, effectively, and efficiently treated with TULSA. There is no bleeding associated with the procedure; no hospital stay is required; and most TULSA patients report quick recovery to their normal routine. TULSA-PRO® is CE marked, Health Canada approved, and 510(k) cleared by the U.S. Food and Drug Administration (“FDA”).
Profound is also commercializing Sonalleve®, an innovative therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases. Sonalleve® has also been approved by the China National Medical Products Administration for the non-invasive treatment of uterine fibroids and has FDA approval under a Humanitarian Device Exemption for the treatment of osteoid osteoma. The Company is in the early stages of exploring additional potential treatment markets for Sonalleve® where the technology has been shown to have clinical application, such as non-invasive ablation of abdominal cancers and hyperthermia for cancer therapy.
For further information, please contact:
Stephen Kilmer
Investor Relations
skilmer@profoundmedical.com
T: 647.872.4849
FAQ
When will Profound Medical (PROF) release Q4 and full year 2024 earnings?
How can investors join Profound Medical's Q4 2024 earnings call?
Where can I find the replay of Profound Medical's Q4 2024 earnings call?
What time is Profound Medical's (PROF) Q4 2024 earnings call?
